Immunotherapy for Kidney Cancer in India: Options, Who May Be Eligible and Cost Factors

Quick answer: Immunotherapy is an established option for some people with advanced renal cell carcinoma, the most common type of kidney cancer. In India, regulators have approved pembrolizumab with axitinib as first-line treatment for advanced disease and pembrolizumab as adjuvant treatment after kidney surgery in people at increased risk of recurrence, and nivolumab is approved for advanced disease after prior therapy. Whether any of these suits you depends on your cancer’s stage, risk group, overall health and the current CDSCO label.

Medically reviewed by: [Reviewer name, qualification] | Last reviewed: [DD Month YYYY]

Kidney cancer and why treatment has changed

Renal cell carcinoma (RCC) begins in the lining of the tiny tubes inside the kidney. When it is found early and has not spread, surgery to remove the tumour or the kidney is usually the main treatment, and that is done by a urologic surgeon at a surgical centre. Denvax is not a surgical centre, so surgery is outside what we provide.

For advanced or metastatic disease, medicines matter more. RCC has historically responded poorly to standard chemotherapy. For roughly fifteen years the usual first-line medicines were VEGF-targeted tablets such as sunitinib and pazopanib. Immunotherapy has since changed the picture: several combinations that pair an immune checkpoint inhibitor with a second drug have shown a survival advantage over sunitinib in large trials in people with intermediate- or poor-risk disease. If the idea of checkpoint inhibitors is new to you, start with our overview of types of immunotherapy.

What is approved for kidney cancer in India

Approval in India is granted indication by indication, so it helps to know the specific combinations. Based on published regulatory and trial records:

  • Pembrolizumab with axitinib, first-line for advanced RCC. India’s expert committee recommended this use in May 2023 with a local trial waiver, and the manufacturer announced the regulator’s approval in October 2023.
  • Pembrolizumab alone as adjuvant treatment. This applies to adults with RCC at increased risk of recurrence after nephrectomy, or after nephrectomy and removal of metastatic lesions.
  • Nivolumab for advanced RCC after prior therapy. This is listed among nivolumab’s Indian approvals, and it was the first immunotherapy approved after VEGF-targeted treatment stopped working.
  • Nivolumab with ipilimumab, first-line, for intermediate- or poor-risk advanced RCC. A phase 4 study in India enrolled 101 patients at 11 sites as a condition of approval by the Indian health authorities. Ask your oncologist whether the current label covers this combination for you.

Approved uses in India depend on the current CDSCO label, and labels are updated, so confirm your exact indication with your treating oncologist. Our list of checkpoint inhibitors approved in India gives wider context.

Who may be a candidate?

Oncologists look at several things together, not one test result:

  • Cancer type and stage. Most trials were in clear cell RCC that had spread or could not be removed. Early, localised disease is usually managed with surgery first.
  • IMDC risk group. This is a scoring system built from factors such as blood counts, calcium level, performance status and the time from diagnosis to treatment. In the key pembrolizumab-axitinib trial, no overall survival benefit was seen in the favourable-risk group, while the intermediate- and poor-risk groups did better.
  • Overall health and other conditions. Immunotherapy can trigger immune reactions, so a history of autoimmune disease or the need for long-term steroids or other immune-suppressing medicines changes the discussion. The Indian phase 4 study, for example, excluded people with active autoimmune disease needing such treatment.
  • Brain or other organ involvement. Active, symptomatic spread to the brain was an exclusion in the Indian study and will shape your plan.

One point that surprises families: PD-L1 testing, which guides immunotherapy in some other cancers, has not been shown to predict survival in these kidney cancer trials. Your oncologist may therefore rely on stage, risk group and fitness rather than a PD-L1 number. Any tests you need are performed at a diagnostic laboratory or hospital; Denvax does not offer cancer testing or diagnostics, but our doctors will review the reports you bring. Our guide on immunotherapy eligibility explains how these decisions are generally made.

What the trial evidence does and does not tell you

The pembrolizumab-axitinib approval rested on the KEYNOTE-426 trial of 861 previously untreated people with advanced RCC. In the reported results, median progression-free survival was 15.1 months with the combination versus 11.1 months with sunitinib, and estimated survival at 12 months was 90% versus 78%. These are group averages from a trial population, not predictions for any individual, and they came mostly from patients treated outside India. Benefit varies from person to person, and some people do not respond. Please read our article on immunotherapy success rates by cancer type to see why single numbers need care.

Side effects to expect and watch for

Checkpoint inhibitors can cause the immune system to act on healthy tissue. Immune-mediated reactions can affect the lungs (pneumonitis), bowel (colitis), liver (hepatitis), hormone glands (thyroid, adrenal), kidneys and skin, and some can be serious. In the pembrolizumab-axitinib trial, grade 3 or higher adverse events were reported in about three in four people on the combination, similar to the sunitinib group, and liver toxicity was the most common reason for stopping. Axitinib itself can raise blood pressure and cause diarrhoea or tiredness.

Report new cough or breathlessness, persistent diarrhoea, yellowing of the eyes or skin, severe tiredness, rash or sudden weight change to your treating team promptly rather than waiting for the next visit. Our pages on immunotherapy side effects and what to expect during immunotherapy give practical detail.

What shapes the cost of immunotherapy for kidney cancer

We have not quoted a total because the figure depends on choices your doctors make with you. The main drivers are:

  • Which medicine and combination you are prescribed. Pembrolizumab and nivolumab are priced differently; see our guides to Keytruda pricing and nivolumab pricing (the latter once it is published).
  • Dose, vials per infusion and number of cycles, which are set by your schedule and response.
  • The partner drug. Axitinib is a daily tablet that runs alongside the infusions and adds its own cost.
  • Hospital day-care charges, monitoring blood tests and scans.
  • Insurance or scheme coverage, which depends on the approved indication and pre-authorisation.

Ask for an itemised estimate that separates drug cost, day-care and monitoring, and review our immunotherapy cost overview before you compare quotes.

Where Denvax fits in

Denvax Cancer Center in Vasant Vihar, New Delhi, has treated over 25,000 patients since 2004 and offers chemotherapy, radiotherapy, targeted therapy and dendritic cell immunotherapy. Targeted therapy and immunotherapy are both part of the modern kidney cancer toolkit, and our doctors can discuss which options may be relevant to your reports. Dendritic cell immunotherapy is not a replacement for approved standard treatment; whether it has any role alongside your plan is a question to raise with the Denvax doctors and your own oncologist. You can read how it works in our dendritic cell therapy patient guide.

Frequently asked questions

Is immunotherapy approved for kidney cancer in India?

Yes, for specific uses. Pembrolizumab with axitinib for first-line advanced RCC, pembrolizumab as adjuvant treatment after surgery in higher-risk patients, and nivolumab after prior therapy have Indian approvals. Check the current CDSCO label for your exact situation.

Does PD-L1 testing decide whether I get immunotherapy for kidney cancer?

Generally not. Studies in advanced RCC have not shown PD-L1 status to correlate with survival, so doctors rely more on stage, IMDC risk group and overall fitness.

Can immunotherapy replace surgery for kidney cancer?

For localised disease, surgery is usually the primary treatment, and immunotherapy may be used afterward in selected higher-risk patients. For advanced disease that has spread, medicines are central. This is decided by your oncology and urology team.

How long does immunotherapy for kidney cancer last?

It depends on the regimen and your response. In the pembrolizumab-axitinib trial, pembrolizumab was given for up to two years. In India’s nivolumab-ipilimumab study, treatment ran for up to 52 weeks. Your own schedule is set by your oncologist.

What if immunotherapy stops working or I cannot tolerate it?

Options may include other targeted tablets, a change of combination or supportive care, depending on your situation. Our article on targeted therapy in cancer explains how these medicines work.

Results may vary. Consult your oncologist. This article is for general information and is not medical advice.

Discuss your kidney cancer reports with a Denvax doctor

Bring your biopsy report, scans and current prescription to Denvax Cancer Center, 18 Poorvi Marg, Vasant Vihar, New Delhi 110057.

अपनी बायोप्सी रिपोर्ट, स्कैन और दवाओं के पर्चे के साथ Denvax Cancer Center में परामर्श के लिए संपर्क करें।

Denvax Clinic

Denvax Clinic

You May Also Like

Denvax Clinic: India’s Leading Cancer Centre for Immunotherapy